Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Kyverna Therapeutics, Inc. (KYTX) had Stock-Based Compensation of $8.36M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-127.48M |
|
-- |
|
-- |
|
$142.60M |
|
$-142.60M |
|
$15.13M |
|
$-127.48M |
|
$-127.48M |
|
$-127.48M |
|
$-127.48M |
|
$-127.48M |
|
$-127.48M |
|
$-142.60M |
|
$-140.47M |
|
38.34M |
|
38.34M |
|
$-3.33 |
|
$-3.33 |
|
| Balance Sheet Financials | |
$290.60M |
|
$3.35M |
|
$14.04M |
|
$304.64M |
|
$33.76M |
|
$0.14M |
|
$4.30M |
|
$38.06M |
|
$266.59M |
|
$266.59M |
|
$266.59M |
|
43.22M |
|
| Cash Flow Statement Financials | |
$-114.25M |
|
$-160.90M |
|
$337.11M |
|
$35.21M |
|
$97.17M |
|
$61.96M |
|
|
Stock-Based Compensation |
$8.36M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.61 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-116.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.82% |
|
-47.82% |
|
-41.84% |
|
-47.79% |
|
$6.17 |
|
$-3.04 |
|
$-2.98 |
|